Agenda
All session times listed in the agenda are in Central European Time Zone (CET).
| 10:00 AM - 10:45 AM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10:45 AM - 11:00 AM | Zoran Gavric, TRC (The Regulatory Company) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11:00 AM - 11:30 AM |
Sylwia Jaczewska, a Policy Officer at the European Commission’s Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, brings direct insight into how European cosmetic legislation is evolving. Her work centers on aligning product safety frameworks and fostering policy coherence across sectors. In this session, she will outline the Commission’s priorities for the next phase of the Cosmetic Products Regulation (CPR) — including the Commission’s view on how the expected future changes may affect Annex I and the use of NAM data in CPSR, and Compliance Operators (Responsible Persons, Safety Assessors, and Testing Laboratories) roles, responsibilities, and qualifications. Sylwia Jaczewska, European Commission | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11:30 AM - 12:00 PM |
Gerald Renner, who leads regulatory and scientific affairs at Cosmetics Europe, has long worked to bridge policy intent with operational feasibility. Drawing from years of advocacy and implementation experience, he will discuss how industry can navigate forthcoming CPR updates with a balanced approach to science and practicality. The session explores the joint industry point of view on needed/welcome changes, together with respective alignment and implementation challenges of the upcoming EU regulatory reforms in practice, while fostering constructive engagement between the stakeholders. You will gain perspective on how industry addresses regulatory reform into smarter, risk-based compliance strategies. Gerald Renner, Cosmetics Europe - The Personal Care Association | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 12:00 PM - 12:30 PM |
Kenny Verzijl, from the Dutch NVWA, offers an enforcement authority’s view on how compliance oversight is adapting to new realities. With years of experience in inspection practice and risk-based supervision, he will share how authorities are addressing rising challenges through more efficient, process-oriented approaches. You will gain insight into the shift toward collaborative models of enforcement — including “limited supervision” for trusted RPs — and how stronger RP–CA partnerships can improve both compliance and consumer protection. Kenny Verzijl, NVWA (The Netherlands Food and Consumer Product Safety Authority) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 12:30 PM - 1:30 PM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1:30 PM - 2:00 PM |
This high-level discussion brings together Responsible Persons, regulators, industry leaders, and national authorities to explore what the next iteration of the RP role should look like. The panel will address how to practically addressing the expected future changes affecting RPs role, responsibilities, qualification standards, certification models, etc. The experts will also reflect on the impact of changing market supply chains, sales through digital platforms, and reflect on examples from other regions’s regulatory frameworks. You will gain a practical understanding of how legislation and industry initiatives can converge to strengthen accountability while maintaining efficiency and adequately addressing challenges of the fast evolving marketing and sales concepts. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2:00 PM - 2:30 PM |
This dialogue examines how regulators and RPs can move from compliance tension to collaboration. Panelists will discuss mutual expectations, approaches for shared guidance, harmonised inspection criteria, and the value of transparent communication channels and open dialogue. You will gain ideas for building cooperative relationships that make compliance predictable, credible, and mutually beneficial. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2:30 PM - 3:00 PM | Safety Assessors sit at the core of product safety assurance. This session brings the Safety Assessors and multiple stakeholders together to examine what constitutes a high-quality CPSR and how assessor competence and quality of their work can be consistently demonstrated. From defining the minimum content requirements to evaluating data quality and assessment consistency, experts will discuss how to create reliable CPSRs that stand up to scrutiny. The panel will explore models for qualification and verification and examples of effective practices internationally. You will gain a grounded view of how to assess scientific robustness and regulatory adequacy of CPSRs and how accreditation and guidance could help raise the bar for CPSR quality across the EU. P.S. This session is explored in more detail by ERPA’s safety assessors in a webinar. Don't forget to choose it on the registration page. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3:00 PM - 3:30 PM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3:30 PM - 4:00 PM |
Francesca Rapolla, a leading voice in UK cosmetics regulatory affairs, brings practical insight into how post-Brexit frameworks are developing. Her work at CTPA focuses on bridging regulatory requirements with practical industry needs and scientific understanding across ingredients, formulation, and safety assessment. In this session, she will outline current UK updates, including newly proposed approach to carcinogenicity thresholds and acceptance of NAMs. You will gain clarity on how to maintain compliance across UK-EU borders and manage emerging divergences efficiently. Francesca Rapolla, CTPA (The Cosmetic, Toiletry and Perfumery Association) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4:00 PM - 4:30 PM |
Meredith Petillo, Director of Technical Regulatory & Safety at IBA, brings extensive experience guiding indie and established brands through the evolving U.S. regulatory environment. She will unpack how MoCRA and state-level rules are being applied in practice, highlighting challenges in CPSR practice, knowledge and capacity gaps, and consolidation of requirements. You will gain an understanding of how global brands can reconcile EU–U.S. regulatory differences and adopt consistent approaches to compliance and product safety. Meredith Petillo, IBA (Independent Beauty Association) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4:30 PM - 5:00 PM |
Kimberly Norman, who leads scientific and regulatory initiatives at PCPC, offers a U.S. industry perspective on implementing MoCRA requirements for cosmetic products’ safety. With a focus on evidence-based safety assessment, she will discuss how CIR reviews, NSF/BSR standards, and weight-of-evidence approaches can bridge gaps until formal guidance is issued. You will gain practical understanding of how safety substantiation frameworks are evolving and what this means for globally marketed products. Kimberly Norman, PCPC (Personal Care Products Council) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5:00 PM - 5:30 PM |
Eric Vaillancourt, representing Health Canada and the ICCR Steering Committee, brings a global view of regulatory cooperation in cosmetics. His work centers on advancing harmonised approaches to safety assessment and enforcement. In this session, he will discuss ICCR’s current initiatives, the barriers to global alignment, and the potential of ICCR guidance to serve as a model similar to GHS. You will gain perspective on how harmonisation efforts can reduce complexity while maintaining high safety standards worldwide. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5:30 PM - 5:45 PM | Zoran Gavric, TRC (The Regulatory Company) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6:00 PM - 8:00 PM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8:30 AM - 8:45 AM | Zoran Gavric, TRC (The Regulatory Company) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8:45 AM - 9:15 AM | Professor Mirjam Luijten, a leading researcher in toxicology and non-animal safety assessment, has been instrumental in shaping Europe’s scientific agenda for alternatives to animal testing. She will present the state of the art in NAMs, drawing on projects like PARC and ASPA that link research innovation to regulatory application. You will gain insight into how these new methods can be integrated into CPSRs in practice and what this shift means for the future of safety science. Mirjam Luijten, National Institute for Public Health and the Environment (RIVM); Leiden University | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9:15 AM - 9:45 AM |
Professor Vera Rogiers, one of Europe’s foremost experts in safety assessment of cosmetics and alternative methods, will analyze how Annex I requirements intersect with NAM-derived data. She will discuss defining toxicological profiles, addressing endpoint relevance, how these can be effectively addressed with NAMs, and bridging theoretical and practical interpretation gaps. You will gain a deeper understanding of how guidance could evolve to better accommodate modern safety science. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9:45 AM - 10:15 AM |
Professor Bob van de Water, whose research focuses on molecular mechanisms of toxicity and high-content in-vitro models, will showcase ready-to-use NAMs from ongoing projects such as RiskHunter and PARK. His presentation will demonstrate how these assays can create reliable safety data for cosmetic ingredients and support CPSR documentation. You will better understand practical tools that can enhance safety evidence quality for cosmetic ingredients and its acceptance in product safety assessments. Bob van de Water, Leiden University | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10:15 AM - 10:30 AM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10:30 AM - 11:15 AM | Facilitated Group Exercise led by ERPA Safety Assessors In this guided session, facilitators will lead participants through creating an example CPSR using selected ingredients and accessible NAMs. You will gain hands-on experience in integrating NAM data into structured safety documentation and see how theoretical concepts translate into daily practice. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11:15 AM - 12:00 PM |
Donna Macmillan within ICCS, specializes in developing practical frameworks for applying NAM data in cosmetic safety assessments. She will outline step-by-step approaches to the Read-Across (RAX) method, including analog identification, justification, and interpretation. You will gain confidence in using RAX as a scientifically transparent way to bridge data gaps in CPSRs. Donna Macmillan, PhD, ICCS (International Collaboration on Cosmetics Safety) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 12:00 PM - 12:30 PM |
Experts from TOXYS will present how validated NAM assays such as ToxTracker and ReproTracker can be applied in the cosmetics sector. Their work demonstrates how in-vitro tools can align with CPSR requirements and build confidence among safety assessors and authorities. You will gain a practical view of how to implement these assays and interpret results within a CPR and Annex I regulatory context. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 12:30 PM - 1:30 PM | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1:30 PM - 2:15 PM | Open Group Discussion, led by ERPA Safety Assessors This session invites regulators, assessors and all interested participants from the audience to review and discuss sample CPSRs incorporating NAM data. Through open dialogue, you will gain understanding of how reviewers interpret NAM results, what questions are typically raised, and how transparent documentation can support acceptance. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2:15 PM - 2:45 PM | Panel Discussion – Regulators, ERPA, Safety Assessors, CAs, Industry Representatives In this closing discussion, regulators and industry experts will identify what frameworks and collaborations are still needed to make NAMs a daily reality in CPSR practice. You will gain perspective on where shared standards, training, and communication can most effectively advance safety assessment without animal testing. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2:45 PM - 3:00 PM | Zoran Gavric, TRC (The Regulatory Company) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-Conference Workshop
| 2:00 PM - 3:30 PM | The Cosmetic Product Safety Report (CPSR) is only as strong as the data and methodology behind it! As a prequel to the ERPA Summit session on CPSR quality and reliability, this dedicated webinar takes a deeper dive into what truly defines a high-quality CPSR. It provides practical, step-by-step guidance on ensuring, and demonstrating, the scientific robustness and regulatory adequacy of CPSRs. From defining the minimum content requirements to evaluating data quality and assessment consistency, experts will discuss how to create reliable CPSRs that stand up to scrutiny.
Daniel Burney, Microbiological Solutions Ltd Zoran Gavric, TRC (The Regulatory Company) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||